LivaNova (LIVN) Stock Price, News & Analysis

Company Overview

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves. These products are designed to improve surgical efficiency, reduce complications and support cardiac function during open-heart procedures. The Neuromodulation unit markets vagus nerve stimulation (VNS) systems indicated for the treatment of drug-resistant epilepsy and major depressive disorder, with a focus on therapy customization, long-term safety and patient quality of life.

Formed in 2015 through the merger of Italy-based Sorin Group and U.S.-based Cyberonics, LivaNova combines decades of expertise in cardiovascular and neurological technologies. The company’s management team is led by President and Chief Executive Officer Damien McDonald, who guides global strategy, research and development initiatives. LivaNova continues to expand its geographic footprint through targeted product launches, partnerships and clinical collaborations, underpinned by a commitment to innovation and patient outcomes.

Key Stats

• Today's Range: $83.13 to $85.27
• 50-Day Range: $57.59 to $84.03
• 52-Week Range: $41.01 to $85.27
• Volume: 548,812 shs
• Average Volume: 775,151 shs
• Market Capitalization: $4.62 billion
• P/E Ratio: 43.09
• Dividend Yield: N/A
• Price Target: $80.75
• Consensus Rating: Moderate Buy

LivaNova Stock Analysis - MarketRank™

LivaNova scored higher than 35% of companies evaluated by MarketBeat, and ranked 559th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

LivaNova has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 6 buy ratings, 4 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for LivaNova is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

LivaNova has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 9.65%

Earnings Growth

Earnings for LivaNova are expected to grow by 9.65% in the coming year, from $3.73 to $4.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LivaNova is 43.09, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.49.

Price to Earnings Ratio vs. Sector

The P/E ratio of LivaNova is 43.09, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.35.

Price to Book Value per Share Ratio

LivaNova has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.32% of the float of LivaNova has been sold short.

Short Interest Ratio / Days to Cover

LivaNova has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in LivaNova has recently increased by 3.52%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LivaNova does not currently pay a dividend.

Dividend Growth

LivaNova does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.23

News Sentiment

LivaNova has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for LivaNova this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for LIVN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, LivaNova insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $136,350.00 in company stock.

Percentage Held by Insiders

0.35% of the stock of LivaNova is held by insiders.

Percentage Held by Institutions

97.64% of the stock of LivaNova is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 7/06/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LIVN
• CIK: 1639691
• Web: www.livanova.com
• Phone: 442033250660
• Fax: 281-218-9332
• Employees: 3,300
• Year Founded: 2015

Price Target and Rating

• Average Price Target for LivaNova: $80.75
• High Price Target: $92.00
• Low Price Target: $66.00
• Potential Upside/Downside: -3.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.95
• Trailing P/E Ratio: 43.09
• Forward P/E Ratio: 22.53
• P/E Growth: N/A
• Net Income: -$242.47 million
• Net Margins: 7.48%
• Pretax Margin: 8.54%
• Return on Equity: 16.48%
• Return on Assets: 7.59%

Debt

• Debt-to-Equity Ratio: 0.24
• Current Ratio: 1.33
• Quick Ratio: 1.11

Sales & Book Value

• Annual Sales: $1.39 billion
• Price / Sales: 3.33
• Cash Flow: $4.86 per share
• Price / Cash Flow: 17.29
• Book Value: $21.98 per share
• Price / Book: 3.82

Miscellaneous

• Outstanding Shares: 54,930,000
• Free Float: 54,742,000
• Market Cap: $4.62 billion
• Optionable: Optionable
• Beta: 0.86